Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial

After publication of our article [1], we noted typographical errors in our tables and in the labelling of Figure 3 (Figure 1). There have been no changes to the results or their interpretation.

Figure 1

Kaplan-Meier curve showing probability of survival during the first 28 days according to treatment group, among patients with sepsis. Dexmedetomidine decreased the probability of dying within 28 days by 70%; this beneficial effect was not seen in patients who were not septic (P value for interaction = 0.11 implying an interaction between sepsis and the treatment groups).

In Table 1, 2 and 3 the number of dexmedetomidine patients without sepsis should read 21 instead of the published 20. The numbers in the corresponding text are correct. The corrected tables can be found overleaf.

Table 1 Baseline characteristics of patients with and without sepsis*

Table 2 Outcomes of patients with and without sepsis*

Table 3 Hemodynamic parameters in patients with and without sepsis*

In Figure 3 (Figure 1) in the "Patients at risk" table below the Kaplan-Meier curve, the dexmedetomidine and lorazepam labels are incorrect. The top row should be labeled lorazepam and the bottom row should be labeled dexmedetomidine. The corrected figure can be found overleaf.